Sara C Nilsson
Overview
Explore the profile of Sara C Nilsson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
581
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martin M, Nilsson S, Eikrem D, Fromell K, Scavenius C, Vogt L, et al.
Front Immunol
. 2023 Jul;
14:1203506.
PMID: 37426666
Background: Dysregulated complement activation, increased protein citrullination, and production of autoantibodies against citrullinated proteins are hallmarks of rheumatoid arthritis (RA). Citrullination is induced by immune cell-derived peptidyl-Arg deiminases (PADs), which...
2.
de Jong S, de Breuk A, Bakker B, Katti S, Hoyng C, Nilsson S, et al.
Front Immunol
. 2022 Jan;
12:789897.
PMID: 35069568
Complement factor I (FI) is a central inhibitor of the complement system, and impaired FI function increases complement activation, contributing to diseases such as age-related macular degeneration (AMD) and atypical...
3.
Martin M, Trattner R, Nilsson S, Bjork A, Zickert A, Blom A, et al.
Front Immunol
. 2020 Nov;
11:582737.
PMID: 33133102
Objective: To examine whether C4d plasma levels correlate with treatment response and C4d kidney deposition in systemic lupus erythematosus (SLE) with lupus nephritis (LN). Methods: C4d plasma levels were analyzed...
4.
de Jong S, Volokhina E, de Breuk A, Nilsson S, de Jong E, van der Kar N, et al.
Hum Mol Genet
. 2020 Jun;
29(14):2313-2324.
PMID: 32510551
Factor I (FI) is one of the main inhibitors of complement activity, and numerous rare coding variants have been reported in patients with age-related macular degeneration, atypical hemolytic uremic syndrome...
5.
Kraaij T, Nilsson S, van Kooten C, Okroj M, Blom A, Teng Y
Lupus Sci Med
. 2019 Jun;
6(1):e000326.
PMID: 31245016
Objective: Because currently available assays that measure circulating immune complexes (ICx) are suboptimal, a novel assay was recently developed measuring C4d, a stable product of activation of the classical complement...
6.
Kremlitzka M, Geerlings M, de Jong S, Bakker B, Nilsson S, Fauser S, et al.
Hum Mol Genet
. 2018 May;
27(15):2678-2688.
PMID: 29767720
Age-related macular degeneration (AMD) is a progressive disease of the central retina and the leading cause of irreversible vision loss in the western world. The involvement of abnormal complement activation...
7.
Geerlings M, Kremlitzka M, Bakker B, Nilsson S, Saksens N, Lechanteur Y, et al.
JAMA Ophthalmol
. 2016 Dec;
135(1):39-46.
PMID: 27918759
Importance: In age-related macular degeneration (AMD), rare variants in the complement system have been described, but their functional consequences remain largely unexplored. Objectives: To identify new rare variants in complement...
8.
Sjolander J, Byman E, Kulak K, Nilsson S, Zhang E, Krus U, et al.
J Biol Chem
. 2016 Aug;
291(41):21644-21655.
PMID: 27566545
C4BP (C4b-binding protein) is a polymer of seven identical α chains and one unique β chain synthesized in liver and pancreas. We showed previously that C4BP enhances islet amyloid polypeptide...
9.
Mohlin F, Nilsson S, Levart T, Golubovic E, Rusai K, Muller-Sacherer T, et al.
Mol Immunol
. 2015 Mar;
65(2):367-76.
PMID: 25733390
Atypical hemolytic uremic syndrome (aHUS) is a disease of complement dysregulation, characterized by hemolytic anemia, thrombocytopenia and acute renal failure. Mutations in complement inhibitors are major risk factors for development...
10.
Nilsson S, Blom A
Methods Mol Biol
. 2013 Nov;
1100:177-88.
PMID: 24218260
Factor I (FI) is a soluble, 88 kDa glycoprotein present in plasma at a concentration of approximately 35 mg/L. FI inhibits all complement pathways as it degrades activated C4b and...